ANTIMICROBIAL TECHNOLOGIES & DRUG DELIVERY PLATFORMS
With
Associate Professor Aaron Elbourne, RMIT University, Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | January 2026
Dr Aaron Elbourne is an ARC DECRA Fellow, Jack Brockhoff ECR Fellow, and Associate Professor within the School of Science at STEM Hub. A leader in nanomaterials, soft matter science, and interface research, Aaron’s work addresses critical challenges in health and the environment.
Since becoming an independent researcher, Aaron has held continuous funding from prestigious funders, including the Australian Research Council (ARC) and the National Health and Medical Research Council (NHMRC). His research is characterised by its interdisciplinary approach, combining chemistry, materials science, and engineering. His pioneering contributions to colloid therapeutics and soft matter science have driven advancements in diagnostic tools, antimicrobial technologies, and therapeutic delivery systems. His expertise in studying nanomaterial interactions with synthetic and biological membranes has been instrumental in translating scientific discoveries into impactful applications.
Aaron is a dedicated mentor to early-career researchers (ECRs) and students, having supervised and trained numerous postgraduate and doctoral candidates. He has played a key role in securing funding for student training initiatives, including joint PhD scholarships and National Industry PhD programs, which emphasise collaboration between academia and industry.
With a strong focus on translational research, Aaron’s work bridges the gap between fundamental science and practical applications. His leadership in creating innovative technologies, fostering academic-industry partnerships, and empowering future researchers underscores his commitment to advancing science and creating a meaningful impact.
Source: Supplied
You Might also like
-
Identifying biomarkers for immunotherapy using spatial biology
Associate Professor Arutha Kulasinghe is a Principal Research Fellow at The University of Queensland’s Frazer Institute, where he leads the Clinical-oMx Lab. He holds the inaugural Brazil Family Chair in Spatial Medicine and is the founding Scientific Director of the Queensland Spatial Biology Centre at the Wesley Research Institute. He completed his PhD at Queensland University of Technology.
-
Dental care improvements using informatics and artificial intelligence
a member of the Scientific Advisory Committee for Dentroid, a startup in Australia aiming to revolutionise dentistry with laser technology. He has gained extensive experience in various roles at research-intensive institutions across three different continents.
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
https://orcid.org/0000-0002-8562-7325